Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1159-1166

  Zaravinos, Apostolos ^a   Volanis, Dimitrios ^a,b   Lambrou, George I ^c   Delakas, Dimitris ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiogenesis; FGF2; OPN; RHOC; Urinary bladder; VEGFA

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; OSTEOPONTIN; RAS HOMOLOG GENE FAMILY MEMBER C; RHEB PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; REFERENCE VALUES; RHO GTP-BINDING PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866455864     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1948     Document Type: Article

References (30)

1. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
2. Jayet C, Deperthes D and Leisinger HJ: Angiogenesis and bladder cancer: trendy prognostic factor or new therapeutic target? Ann Urol (Paris) 36: 258-263, 2002 (Article in French). (Pubitemid 34773809)
3. Bochner BH, Cote RJ, Weidner N, et al: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87: 1603-1612, 1995.
4. Donmez G, Sullu Y, Baris S, et al: Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205: 854-857, 2009.
5. Pignot G, Bieche I, Vacher S, et al: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol 56: 678-688, 2009.
6. Chikazawa M, Inoue K, Fukata S, Karashima T and Shuin T: Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 75: 335-345, 2008.
7. El-Tanani MK: Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 13: 4276-4284, 2008.
8. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004. (Pubitemid 38746324)
9. Ang C, Chambers AF, Tuck AB, Winquist E and Izawa JI: Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96: 803-805, 2005. (Pubitemid 41391385)
10. Zaravinos A, Lambrou GI, Volanis D, Delakas D and Spandidos DA: Spotlight on differentially expressed genes in urinary bladder cancer. PloS One 6: e18255, 2011.
11. Wang W, Wu F, Fang F, Tao Y and Yang L: RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. Cancer Sci 99: 2012-2018, 2008.
12. Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687, 1999. (Pubitemid 29214373)
13. Kamai T, Tsujii T, Arai K, et al: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641, 2003. (Pubitemid 36842107)
14. Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V and Spandidos DA: Expression profile of Rho kinases in urinary bladder cancer. J BUON 16: 511-521, 2011.
15. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D and Spandidos DA: Implication of RAF and RKIP genes in urinary bladder cancer. Pathol Oncol Res 17: 181-190, 2011.
16. Boulalas I, Zaravinos A, Delakas D and Spandidos DA: Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers 24: 17-21, 2009.
17. Zaravinos A, Lambrou GI, Boulalas I, Delakas D and Spandidos DA: Identification of common differentially expressed genes in urinary bladder cancer. PloS One 6: e18135, 2011.
18. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
19. Ke HL, Chang LL, Yang SF, et al: Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 29: 703-709, 2011.
20. Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6: 4866-4873, 2000. (Pubitemid 32110431)
21. Yang S, Wu X, Luo C, Pan C and Pu J: Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. World J Urol 28: 473-478, 2010.
22. Shariat SF, Youssef RF, Gupta A, et al: Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 183: 1744-1750, 2010.
23. Zachos I, Konstantinopoulos PA, Tzortzis V, et al: Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 19: 875-887, 2010.
24. Chakraborty G, Jain S and Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161, 2008. (Pubitemid 351380116)
25. Marzioni D, Lorenzi T, Mazzucchelli R, et al: Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol 22: 627-638, 2009.
26. Gan Y, Wientjes MG and Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 23: 1324-1331, 2006. (Pubitemid 43946154)
27. Gravas S, Bosinakou I, Kehayas P and Giannopoulos A: Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int 73: 173-177, 2004. (Pubitemid 39482731)
28. Stoletov K, Montel V, Lester RD, Gonias SL and Klemke R: High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci USA 104: 17406-17411, 2007. (Pubitemid 350219851)
29. Abe H, Kamai T, Tsujii T, et al: Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 29: 155-161, 2008.
30. Horiuchi A, Imai T, Wang C, et al: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83: 861-870, 2003. (Pubitemid 36723695)